{"name":"Alvotech Swiss AG","slug":"alvotech-swiss-ag","ticker":"","exchange":"","domain":"alvotechswiss.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"AVT03","genericName":"AVT03","slug":"avt03","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"Adalimumab biosimilar","genericName":"Adalimumab biosimilar","slug":"adalimumab-biosimilar","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"Adalimumab originator","genericName":"Adalimumab originator","slug":"adalimumab-originator","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"Simponi","genericName":"Simponi","slug":"simponi","indication":"Ankylosing spondylitis","status":"marketed"},{"name":"Simponi (Golimumab)","genericName":"Simponi (Golimumab)","slug":"simponi-golimumab","indication":"Rheumatoid Arthritis","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"AVT05","genericName":"AVT05","slug":"avt05","indication":"Other","status":"phase_1"},{"name":"AVT80","genericName":"AVT80","slug":"avt80","indication":"Other","status":"phase_1"},{"name":"Geographical region 1 Entyvio","genericName":"Geographical region 1 Entyvio","slug":"geographical-region-1-entyvio","indication":"Other","status":"phase_1"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"Eylea HD (aflibercept HD)","genericName":"Eylea HD (aflibercept HD)","slug":"eylea-hd-aflibercept-hd","indication":"Neovascular (wet) age-related macular degeneration","status":"phase_3"},{"name":"Eylea® (Aflibercept)","genericName":"Eylea® (Aflibercept)","slug":"eylea-aflibercept","indication":"Wet age-related macular degeneration (wAMD)","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"AVT04","genericName":"AVT04","slug":"avt04","indication":"Metastatic colorectal cancer","status":"phase_3"}]}],"pipeline":[{"name":"AVT03","genericName":"AVT03","slug":"avt03","phase":"phase_3","mechanism":"AVT03 is a biosimilar of adalimumab that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation.","indications":["Rheumatoid arthritis","Crohn's disease","Ulcerative colitis","Psoriasis","Ankylosing spondylitis"],"catalyst":""},{"name":"AVT05","genericName":"AVT05","slug":"avt05","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"AVT80","genericName":"AVT80","slug":"avt80","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Adalimumab biosimilar","genericName":"Adalimumab biosimilar","slug":"adalimumab-biosimilar","phase":"phase_3","mechanism":"Adalimumab biosimilar is a TNF-alpha inhibitor that binds to and neutralizes tumor necrosis factor-alpha, reducing inflammatory signaling.","indications":["Rheumatoid arthritis","Psoriatic arthritis","Ankylosing spondylitis","Crohn's disease","Ulcerative colitis"],"catalyst":""},{"name":"AVT04","genericName":"AVT04","slug":"avt04","phase":"phase_3","mechanism":"AVT04 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells.","indications":["Metastatic colorectal cancer","Non-squamous non-small cell lung cancer","Metastatic breast cancer","Renal cell carcinoma"],"catalyst":""},{"name":"Adalimumab originator","genericName":"Adalimumab originator","slug":"adalimumab-originator","phase":"phase_3","mechanism":"Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.","indications":["Rheumatoid arthritis","Psoriasis","Crohn's disease","Ulcerative colitis","Ankylosing spondylitis"],"catalyst":""},{"name":"Eylea HD (aflibercept HD)","genericName":"Eylea HD (aflibercept HD)","slug":"eylea-hd-aflibercept-hd","phase":"phase_3","mechanism":"Eylea HD is a high-dose formulation of aflibercept, a VEGF trap that binds and inhibits vascular endothelial growth factor to reduce abnormal blood vessel growth and leakage in the eye.","indications":["Neovascular (wet) age-related macular degeneration","Diabetic macular edema","Retinal vein occlusion","Myopic choroidal neovascularization"],"catalyst":""},{"name":"Eylea® (Aflibercept)","genericName":"Eylea® (Aflibercept)","slug":"eylea-aflibercept","phase":"phase_3","mechanism":"Aflibercept is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit abnormal blood vessel growth in the eye.","indications":["Wet age-related macular degeneration (wAMD)","Diabetic macular edema (DME)","Macular edema following retinal vein occlusion (RVO)","Diabetic retinopathy"],"catalyst":""},{"name":"Geographical region 1 Entyvio","genericName":"Geographical region 1 Entyvio","slug":"geographical-region-1-entyvio","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Simponi","genericName":"Simponi","slug":"simponi","phase":"marketed","mechanism":"Tumor necrosis factor","indications":["Ankylosing spondylitis","Juvenile idiopathic arthritis","Nonradiographic axial spondyloarthritis","Polyarticular juvenile idiopathic arthritis","Psoriasis with arthropathy"],"catalyst":""},{"name":"Simponi (Golimumab)","genericName":"Simponi (Golimumab)","slug":"simponi-golimumab","phase":"phase_3","mechanism":"Simponi (Golimumab) is a monoclonal antibody that selectively binds to and inhibits tumor necrosis factor-alpha (TNF-alpha), a pro-inflammatory cytokine.","indications":["Rheumatoid Arthritis","Psoriatic Arthritis","Ulcerative Colitis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQd1BSdGNva0tpWmhrQ0lfb0F3M3JGX093cTRZczBURnhXVmkwU1VFenJVcndjM1o5X1dVc3YtekpmczhDdHVTSUJ1V3BGdUpvNHdyZElfZjh3V291MEhiYWFqNHp6NDRJZE12ZmRIR1EtajFndjJEUjVXYjJQNENUcnlvZ3FQR21mRHI5Uk9hNFc4U0RZc0Z1bmNB?oc=5","date":"2026-04-07","type":"regulatory","source":"openPR.com","summary":"Chronic Plaque Psoriasis Market Size is to Show Remarkable Growth Trends from 2024 to 2034, estimates DelveInsight - openPR.com","headline":"Chronic Plaque Psoriasis Market Size is to Show Remarkable Growth Trends from 2024 to 2034, estimates DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxQNWppRHphdW5tR3YtRFplQzlmRzVTRGxUTjNwWVhic0lreXVBR3lYN3VibDBRVVdBZnhsUnBjdHl0cGE2WmlJODNxblJNakczRDR2b0tTTXZWV3pDU0tZNENsTVl1anVaLThxZHQwWFlkdjMyeTkwYkZWMTNDRExib0U2U0VMS0p4a3N1MUcxVWQ2SWNxWkhPZkk4RENjdDVtSUNRSGt1dTNLTUczT3lnSWlPTDFVd3FGNFpadHBkMTFLdw?oc=5","date":"2026-03-21","type":"regulatory","source":"AD HOC NEWS","summary":"Alvotech stock advances on biosimilar approvals and capacity expansion amid strong biotech momentum - AD HOC NEWS","headline":"Alvotech stock advances on biosimilar approvals and capacity expansion amid strong biotech momentum","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPWVRxV1RpY3FqQzcyYUVfWWhHYWtFRTI1NU5pM0VrOG5rRlRLbnhwbkhXd0VSWlZiVVRlNnNmOFdSd015dTktcUp6SGdDVHlySDdUeHp0ZWtSU3ZvQ0I0QkNIM20wVVpRdkQ3SHlPYkFBZWR1RncyaHdiSzBZMGJKMWt2NHdpZ0xLX0Y1endpNldSSUQtVlY0amVnMnZETm9JY2V6NHhseTdVTElacnpTaTJRQlo4dw?oc=5","date":"2025-12-19","type":"deal","source":"Fierce Pharma","summary":"Partners Alvotech, Teva eye 2026 Eylea biosimilar launch in US with Regeneron settlement - Fierce Pharma","headline":"Partners Alvotech, Teva eye 2026 Eylea biosimilar launch in US with Regeneron settlement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOalRLQUIwQVFDeGJXQTF6T0gzQWVSZlNWMlhzNENPbjBGckJ5dVdUcE8zRUZNYk9IU0IyZXZVdzFLUG9uekxqOTNfT1g0R3BFMzJiOGotMHd4dWlqQjVXVjNoVXpkUUdPZlFQNmJ5bVlvc3FmQUJtYzlNcU1ESjhRY3FfNGZRXzMzTjBFWEpudWZROHZoOWZELTQ4RW1aVDdvTVItNTNLNS1HTkNBbTV0T0VEOEdKWnBJeHB3b25Ubw?oc=5","date":"2025-11-10","type":"pipeline","source":"Stock Titan","summary":"Alvotech (NASDAQ: ALVO) allowed to manufacture AVT06 in UK under SPC waiver - Stock Titan","headline":"Alvotech (NASDAQ: ALVO) allowed to manufacture AVT06 in UK under SPC waiver","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwJBVV95cUxPNGc2U0xPX1A1cWhMcG51bURrZkdIUmc1VGZkRE1TcEpueEFvRUpQQlZzbDd5R3lVNkxZYi02SV9tV0wzWGthRkRRRjdCUkN3dUJDMGw4NkVlVDNycVRVTlgzZDE1QTdKX0dOblVBbTBZMkQwVngyU2RKZWdXMnBhVzZkN1F1UTR1NXdpbzJ0eF9NOERWUjRNbm5oR0JTTmUwVE5KSjFfUFYtQkNTdGhqNkt4MjFqTWRHT2xhWnJKYUJkN3lmZ2p2RmptOXRHd1g5NTRBWERKWjY0SU02UzRVTktDVjFjd2h4YmZvNEpZUkpCaVZPSWJ4N1kxRFpzSXBIa3lxNW16a2ZRX0g3aTBHR0wyQnNibWRBMTVN?oc=5","date":"2025-11-06","type":"pipeline","source":"GlobeNewswire","summary":"Alvotech and Advanz Pharma Receive Marketing Authorisations - GlobeNewswire","headline":"Alvotech and Advanz Pharma Receive Marketing Authorisations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAJBVV95cUxQSmJEVEN3MFkwLTVUaE5VMmR1Ml9zZUM1VUlFSGFPMHlRUnNqZVJjRk0tU0dmUl9JVk14bFJEUFJ1QWQyR3l6UnBza0JDcFQyMDZfb25PRXRaRjFuWW9pU0lqOTdJN3NuaGp0Y3hZbVpaMVZWcFVwaGExTGhHeVA1dzJjeTVyYndkTFRMaFNHY3lCQUpQcGNsY0x0LXF5d2hyRExWcElDcThXeDdKSngxTUxNR0xtaWJJck54b1F1OWxkYlJNeG9Ha2kzU2dFN19oUE9zWFVVLU1lNnF3UlNnUGp0Q3ZDelNpVS00bDlOUWV2d0xMV2toNkFwUEFmYTZqeFU4cDc5UHg4SktSZDM1SXRZZEhnVWZRWTE3QkxoZFFFWHRJMG9INWxMQVNDRTBKaUdjR1NFd05zNXpvQmRhMU5pLV80TEl0Q2tHeA?oc=5","date":"2025-11-04","type":"pipeline","source":"Finansavisen","summary":"Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update - Finansavisen","headline":"Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provid","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxNNW5WZUtpWlBGeW9aUC1YVTdTU3kwcGRGalA3ZjZsQll4SHhRQVFTSV9nVkU3WHoyZHlCYzJZU1Jab0thQjkyb0FkLWYwZ1AzN3VIT2RQclR5emNmazctYk1RNVRteFN6ZG1jRU1KdTJyQUVQUjN2eWdjNlhoVEFpWjdEWkFISk9FLVJLbWRTYlNMMkR0S2RvZEs2LWM2NVlRZE5wVkU3UDE1SWhMWEVsWl9xWkowVDlaVlBhY2hwS1hjQWJWX0psdG43XzBHVlFWOXc?oc=5","date":"2025-10-22","type":"pipeline","source":"Quiver Quantitative","summary":"Alvotech Announces Key Leadership Changes in Global Business Development and Commercial Operations Team - Quiver Quantitative","headline":"Alvotech Announces Key Leadership Changes in Global Business Development and Commercial Operations Team","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxPYk5PeFJjWjRrZkgxQUw1UWwyWG13MWJVS0dHMTkxREpDQ081SEtsN205NXhlMkJ0eWtfd1BSNVk0NUNjcThkS0ZDVUdacUVxV2tyNTY0cVltLVlaTXhVemoxQXlmTzJhdmZ6eVFxNnJUenpReFpHX3BIREVoZ2lxV3BUaERPUQ?oc=5","date":"2025-07-09","type":"deal","source":"Contract Pharma","summary":"Alvotech Acquires Ivers-Lee Group - Contract Pharma","headline":"Alvotech Acquires Ivers-Lee Group","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwJBVV95cUxPQnN6ejJBc1I5UFEtZGJBeGowQU55alF5NGdJSUtzX3FRMTFMcjh3c0paU09ydWJwbnJnZGhCTlItU0twTVFhZ2pvbW1fM2ZDUnJKVzlVRDhRTkZtd1VPTXpPTS0xSDVyVWxlU2hocGJNNGpkMkItanNrYm45cDhrRWY5NGttS2hoVE1FRHZZQW5Kb1I4VnhWcXdzXzhBYlByX1BrQjlScjUzeDZlWnBsZV9lcTQ3Vl9KdGp5RmpHQzlNS2tqdklLQlVoMk81a0ZVb0tQandpRUN0aTNnUFc1NDNLNTh2cXFXbnNfMGZEb2xSSnBuZDN3bHZxaElHRnRoNzRVYWdGRC1vSUNFdlluLWRsYUM1QTQ?oc=5","date":"2025-03-18","type":"regulatory","source":"Business Wire","summary":"Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® - Business Wire","headline":"Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Pro","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQMG5HN0RRR3BWY3dxcHd0T0k3ajlGR2RaSTVPbTVtbngzNkxiNkJUM2tKSHQ2alNnVzBULTlFTzlxWG44TGFWRVEwN1duYWFuX0REYTM3dGhhdzZqZFN0czB1bDluT2lISVdUM2l4YVplME1MZ1ZwWjNZbFg0T1o1SG80ZFBmaG1YaGxIVXBETGtLYkZX?oc=5","date":"2023-09-02","type":"earnings","source":"Center for Biosimilars","summary":"Alvotech Earnings Jump Nearly 600% Year Over Year - Center for Biosimilars","headline":"Alvotech Earnings Jump Nearly 600% Year Over Year","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNUEJNeEJOenhEN1kzZ3pXMzFYZi1udkcxbXMzSVE2blFLUVladkhZdS1Ccl9Mc0FPSWZiLUZodERWM2IzUExqYXBDbk1JT25zUHE5amwtWXVRc3ZqRkRBeDRFc1NKZkFiY25MMU9meUo4Y0hOVDVNUURlN1llbEFIcXhWdHFDU3gzZVdRV3poUUtLMHNHUlVr?oc=5","date":"2023-05-29","type":"patent","source":"Drug Store News","summary":"Alvotech, Advanz Pharma to commercialize 5 proposed biosimilars in Europe - Drug Store News","headline":"Alvotech, Advanz Pharma to commercialize 5 proposed biosimilars in Europe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxNdkFQa0hWREg2WUVrUnlVMnFJbTNfcGlsVEx5N2VESS0yV0Zvek1fQVhfakRadjZWcUMwLTI0VmtvUUh3WVI5b3QxRll4VkVDQXZRdGpUVXRsVGNYbFhUZXJCRmJfUTRUeU1jQUV3R0l5aEE1WUhvVkNVMktfU3VKYlpFQQ?oc=5","date":"2021-07-04","type":"deal","source":"Generics and Biosimilars Initiative","summary":"Fuji Pharma acquires stake in Alvotech - Generics and Biosimilars Initiative","headline":"Fuji Pharma acquires stake in Alvotech","sentiment":"neutral"}],"patents":[],"drugCount":11,"phaseCounts":{"phase_3":7,"phase_1":3,"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}